Representative Matters
REFERENZMANDATE
代表事项
Mergers and Acquisitions
- BlueRock Therapeutics, a biotechnology company focusing on developing stem cell therapies, in its sale to Bayer
- PillPack, an online pharmacy, in its sale to Amazon
- Repligen, a life sciences company focused on bioprocessing technology leadership, in numerous acquisitions including its acquisitions of C Technologies and Spectrum
- AppNexus, an ad tech company, in its acquisitions of Open AdStream, YieldEx, MediaGlu and Realmedia Latin America and in its sale to AT&T
- Exosome, a company that develops and sells diagnostics that test for exosomes, in its sale to Bio-Techne
- Virtustream, a cloud management firm, in its sale to EMC
- Promedior, a clinical stage immunotherapy company, in its grant to Bristol-Myers Squibb of an exclusive right to acquire Promedior
- OVH, a cloud service provider, in its acquisition of the vCloud Air business from VMware
- Teva Pharmaceuticals, a pharmaceutical company, in its sale of its animal health business to Bayer Healthcare and its sale of four targeted oncology development programs to Ignyta
- Interactions, a technology company, in its acquisition of the AT&T Watson technology program
- Bomgar, a provider of enterprise remote support solutions, in TA Associates’ majority investment in Bomgar
- Numara Software, a provider of integrated IT management solutions, in its sale to BMC Software
Financings and Joint Ventures
- Century Therapeutics, a biotechnology company focusing on developing stem cell therapies for cancer, in its joint venture with Bayer
- Versant Ventures, a venture capital firm focused on the healthcare sector, in its formation of BlueRock Therapeutics and joint venture with Bayer
- CRISPR Therapeutics, a biotechnology company, in its formation of Casebia Therapeutics and joint venture with Bayer
- Arvinas, a biotechnology company, in its joint venture with Bayer focused on developing new agricultural products
- BridgeBio, a biotechnology company that focuses on identifying and advancing transformative medicines for genetic diseases, in its $299 million financing
- Ginkgo Bioworks, a biotechnology company, in its joint venture with Bayer that is focused on the plant microbiome
- MyoKardia, a company developing precision therapies for genetic heart disease, in its $46 million financing
- Phreesia, a healthcare point-of-service platform, in its $30 million financing led by LLR Partners
- Global Blood Therapeutics, a biopharmaceutical company developing therapeutics for the treatment of severe blood disorders, in its $48 million financing
Initial Public Offerings
- BridgeBio, a biotechnology company that focuses on identifying and advancing transformative medicines for genetic diseases, in its initial public offering
- MyoKardia, a company developing precision therapies for genetic heart disease, in its initial public offering
Professional Experience
Prior to joining Goodwin in 2011, Mr. Breen was an associate in the corporate group at Simpson Thacher & Bartlett in New York.
